Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6035943 | PMC |
| http://dx.doi.org/10.21037/jtd.2018.05.35 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Role of an Interdisciplinary Left-Ventricular Assist Device (LVAD) Outpatient Clinic in Long-Term Survival After Hospital Discharge: A Decade of HeartMate III Experience in a Non-Transplant Center.
Biomedicines
July 2025
Department of Thoracic and Cardiovascular Surgery, Tübingen University Hospital, 72076 Tübingen, Germany.
Background: In advanced heart failure patients implanted with a fully magnetically levitated HeartMate 3 (HM3) Abbott left ventricular assist device (LVAD), it is unknown how the role of the LVAD outpatient clinic may affect the long-term survival after hospital discharge. Our objective is to share our standardized protocol for outpatient care, to describe the role of the LVAD outpatient clinic in postoperative long-term care after LVAD implantation, and to report survival.
Methods: We retrospectively reviewed all patients implanted with HM3 LVAD in our institute between September 2015 and January 2025.
A Milestone in Cardiac Care in Iraq: One-year Follow-up after the Nation's First Continuous-flow Left Ventricular Assist Device Implantation, Paving the Way for Heart Transplantation.
Heart Views
July 2025
Department of Cardiac, Thoracic, Transplantation, and Vascular Surgery, Hannover Medical School, Hannover, Germany.
The first successful implantation of the HeartMate 3 LVAD in Iraq represents a transformative achievement in the nation's medical history. Conducted collaboratively by German and Iraqi teams in December 2023, the procedure addressed end-stage heart failure in a 60-year-old male. Despite significant healthcare challenges, the patient's functional status improved markedly, moving from New York Heart Association Class IV to Class I within a year.
View Article and Find Full Text PDFFirst Successful HeartMate 3 Implantation in the Pediatric Population in Brazil.
Transplant Proc
September 2025
Instituto do Coração (InCor) Hospital das Clinicas da Faculdade de Medicina da Universidade, de Sāo Paulo, SP, Brazil.
The purpose of this study was to describe the first successful Heartmate 3 implantation in the pediatric population in Brazil.
View Article and Find Full Text PDFEnhancing Left Ventricular Assist Device Usability: A Comparative Simulation Study of CorWave and HeartMate 3 Peripherals.
ASAIO J
May 2025
From the Department of Cardiac and Thoracic Aortic Surgery, Medical University of Vienna, Vienna, Austria.
Left ventricular assist devices (LVADs) improve outcomes but often compromise quality of life (QoL) due to usability issues with wearables. This study compared the usability of CorWave LVAD (CW) peripherals prototypes to HeartMate 3 LVAD (HM3) peripherals through a cross-sectional, simulation-based approach involving LVAD-naive laypeople, and heart transplantation (HTX) patients post-LVAD support. Simulations encompassed six tasks, measuring initial success rates, duration to success, pump-off time, and a post-scenario survey.
View Article and Find Full Text PDFA multi-site study of clinician perspectives in the lifecycle of an algorithmic risk prediction tool.
SSM Qual Res Health
June 2025
Baylor College of Medicine, Center for Medical Ethics and Health Policy, United States.
Recent advancements in the performative capacities of artificial intelligence (AI), machine learning (ML), and algorithmic-based tools open up numerous applications in modern medicine. There are, however, few studies that track the whole lifecycle of a digital healthcare tool as it evolves from conception, to design, and deployment in real world settings-especially with a focus on the social dynamics amongst the end-users of the tool: clinicians. In this paper, we present data from a multi-site, 5-year study focused on the development and deployment of an algorithmic risk calculator (HeartMate 3 Risk Score) into a validated and efficacy tested clinical decision support system (CDSS) for patients and clinicians engaging in shared decision making about left ventricular assist device (LVAD) therapy for advanced heart failure.
View Article and Find Full Text PDF